Gilead Sciences Inc (GILD)
GILD (NASDAQ:Drugs)
$56.30
+1.34
+2.44%
Today's Range: 54.65 - 56.43 |
GILD Avg Daily Volume: 11,757,000
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 13,909,763 |
| YTD Performance: 49.65%
|
| Open: $55.48 |
| Previous Close: $54.96 |
| 52 Week Range: $24.12 -
$57.10 |
| Oustanding Shares: 1,525,355,825 |
| Market Cap: 83,833,556,142 |
6-Month Chart
TheStreet Ratings Grade for GILD
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
16 |
16 |
16 |
16 |
| Moderate Buy |
2 |
3 |
3 |
3 |
| Hold |
3 |
3 |
3 |
3 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.38 |
1.39 |
1.39 |
1.39 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
09/07/04 |
| Price Earnings Ratio: |
30.70 |
|
| Price Earnings Comparisons: |
| GILD |
Sector Avg. |
S&P 500 |
| 30.70 |
30.80 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
32.12%
|
118.30%
|
190.95%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
15.70 |
0.38 |
0.11 |
| Net Income |
0.00 |
-0.02 |
-0.01 |
| EPS |
-7.60 |
0.17 |
0.05 |
| Earnings for GILD: |
| EBITDA |
4.29B |
| Revenue |
9.70B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.47 |
$0.47 |
$1.90 |
$2.76 |
| Number of Analysts |
3 |
3 |
3 |
3 |
| High Estimate |
$0.47 |
$0.48 |
$1.96 |
$3.22 |
| Low Estimate |
$0.46 |
$0.44 |
$1.83 |
$2.36 |
| Prior Year |
$0.47 |
$0.47 |
$1.73 |
$1.90 |
| Growth Rate (Year over Year) |
-0.71% |
-1.75% |
9.83% |
45.26% |
May 17, 2013 | 7:53 AM EDT
GILD estimates were increased to include tenofovir alafenamide (TAF) after positive feedback from doctors, said UBS. Price target goes ...
By
Adam Feuerstein
May 16, 2013 | 2:09 PM EDT
May 15, 2013 | 7:11 AM EDT
Bank of America Merrill Lynch Health Care Conference (Day 2 of 3) - 05/14/13 - 05/16/13 Las Vegas, NV
| May 14, 2013 | 7:16 PM EDT
At this rate, the S&P could hit 1700 by the end of the month!
| May 13, 2013 | 6:44 PM EDT
We see a lot of short squeezes as money rotates into laggard groups.
| May 10, 2013 | 12:52 PM EDT
Just a natural change in leadership.
| May 09, 2013 | 6:44 PM EDT
Rest is key in bull markets in order to sustain a longer-term rally.
By
Adam Feuerstein
May 09, 2013 | 9:39 AM EDT
May 08, 2013 | 7:30 AM EDT
Gilead Sciences Annual Stockholders Meeting - 1PM
| May 03, 2013 | 7:23 AM EDT
Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.
